CAP, controlled attenuation parameter; LS, liver stiffness; MRE, magnetic resonance elastography; S2-S8: various hepatic segments on magnetic ... received speaker’s fees and research funding from ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of global commercial, he announced on LinkedIn this week. “CAR T-cell therapy has changed ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills in a case that raised questions about the ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...